Tecartus - CAR-T cell therapy: A new form of treatment for refractory / relapsed mantle cell lymphoma

Tecartus® (brexucabtagene autoleucel) is a drug for the treatment of certain types of blood cancer. In particular, it is used to treat relapsed or refractory mantle cell lymphoma (MCL). It is a form of CAR-T cell therapy. This involves genetically modifying the body's own immune cells (T cells) in order to recognise and destroy cancer cells. Since 21 August 2023, doctors in Germany have only been allowed to use Tecartus® to treat mantle cell lymphoma if they document the treatment data in the EMCL registry (Registry of the European Mantle Cell Lymphoma Network). This is a requirement of the Federal Joint Committee (G-BA) as part of an "Real-World effectiveness" data collection (AbD).

The Department of Epidemiology and Health Services Research at the Institute of Medical Biometry, Epidemiology and Informatics (IMBEI) in Mainz collects and analyses data on health-related quality of life during treatment with Tecartus®. The project started in August 2023 and will run until February 2028.

Cooperation partners: III Medical Clinic (Haematology & Oncology), Interdisciplinary Centre for Clinical Studies (IZKS), Department of Medical Documentation (IMBEI), European Mantle Cell Registry (EMCL) 

Funding: Kitepharma / Kite-Gilead